

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

By Valerie A. Wilson

ELI LILLY AND COMPANY

Date February 19, 1999

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ronald N. Hermeling, et al. )  
Serial No. : 09/209,799 )  
Filed : December 11, 1998 ) Attention:  
For : GLUCAGON-LIKE PEPTIDE-1 ) Branch Manager  
CRYSTALS )  
Docket No. : X-10242 )

MAR 10 1999

GROUP 1800

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents  
Washington, D. C. 20231  
Attention: Box Sequence  
Sir:


This is in response to a "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures" dated January 29, 1999, noting the absence of an acceptable Sequence Listing.

Enclosed herewith are:

- 1) a copy of the Notice;
- 2) a computer-readable copy of the Sequence Listing pursuant to 37 C.F.R. § 1.821(e);
- 3) a paper copy of the Sequence Listing pursuant to 37 C.F.R. § 1.821(c);

Serial No. 09/209,799

- 4) an affirmation pursuant to 37 C.F.R. § 1.821(f); and
- 5) a Preliminary Amendment amending the specification to include the sequence listing.  
Respectfully submitted,

  
Ronald S. Maciak  
Attorney for Applicants  
Registration No. 35,262  
Phone: 317-276-1664

Eli Lilly and Company  
Patent Division/RSM  
Lilly Corporate Center  
Indianapolis, Indiana 46285

2/19/99



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK  
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	---------------------	-----------------------	---------------------------

09/209,799

12/11/99

HERMELING

R X-10242

0222/0129

NOT ASSIGNED

ROBERT A. CONRAD  
ELI LILLY AND COMPANY  
PATENT DIVISION/RSM  
LILLY CORPORATE CENTER  
INDIANAPOLIS IN 46285

1646 MAR 10 1999

DATE MAILED:

GROUP 2

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. OTHER: \_\_\_\_\_

**APPLICANT MUST PROVIDE:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- ☒ An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:**

- ☐ For Rules Interpretation, call (703) 306-1123.
- ☐ For CRF submission help, call (703) 308-4212.
- ☐ For PatentIn software help, call (703) 308-6856.

*EN*  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202

**PART 2 - COPY TO BE RETURNED WITH RESPONSE**